Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. 2010

Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, UFSC, Florianópolis, SC, Brazil. ruidsp@hotmail.com

Many studies have shown that deficits in olfactory and cognitive functions precede the classical motor symptoms seen in Parkinson's disease (PD) and that olfactory testing may contribute to the early diagnosis of this disorder. Although the primary cause of PD is still unknown, epidemiological studies have revealed that its incidence is increased in consequence of exposure to certain environmental toxins. In this study, most of the impairments presented by C57BL/6 mice infused with a single intranasal (i.n.) administration of the proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1 mg/nostril) were similar to those observed during the early phase of PD, when a moderate loss of nigral dopamine neurons results in olfactory and memory deficits with no major motor impairments. Such infusion decreased the levels of the enzyme tyrosine hydroxylase in the olfactory bulb, striatum, and substantia nigra by means of apoptotic mechanisms, reducing dopamine concentration in different brain structures such as olfactory bulb, striatum, and prefrontal cortex, but not in the hippocampus. These findings reinforce the notion that the olfactory system represents a particularly sensitive route for the transport of neurotoxins into the central nervous system that may be related to the etiology of PD. These results also provide new insights in experimental models of PD, indicating that the i.n. administration of MPTP represents a valuable mouse model for the study of the early stages of PD and for testing new therapeutic strategies to restore sensorial and cognitive processes in PD.

UI MeSH Term Description Entries
D007266 Inhibition, Psychological The interference with or prevention of a behavioral or verbal response even though the stimulus for that response is present; in psychoanalysis the unconscious restraining of an instinctual process. Inhibition (Psychology),Inhibition, Psychology,Psychological Inhibition,Inhibitions (Psychology),Inhibitions, Psychological,Inhibitions, Psychology,Psychological Inhibitions,Psychology Inhibition,Psychology Inhibitions
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009448 Neurochemistry The study of the composition, chemical structures, and chemical reactions of the NERVOUS SYSTEM or its components. Neurochemistries
D009498 Neurotoxins Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. Alpha-Neurotoxin,Excitatory Neurotoxin,Excitotoxins,Myotoxin,Myotoxins,Neurotoxin,Alpha-Neurotoxins,Excitatory Neurotoxins,Excitotoxin,Alpha Neurotoxin,Alpha Neurotoxins,Neurotoxin, Excitatory,Neurotoxins, Excitatory
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal

Related Publications

Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
November 2009, Molecular and cellular endocrinology,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
May 2016, Proteomics,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
March 1988, Toxicology letters,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
May 1996, Biulleten' eksperimental'noi biologii i meditsiny,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
June 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
August 2013, Human & experimental toxicology,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
October 2015, Journal of toxicologic pathology,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
January 2014, Neurotoxicity research,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
July 1998, Neuroscience,
Rui D S Prediger, and Aderbal S Aguiar, and Argelia Esperanza Rojas-Mayorquin, and Claudia P Figueiredo, and Filipe C Matheus, and Laure Ginestet, and Caroline Chevarin, and Elaine Del Bel, and Raymond Mongeau, and Michel Hamon, and Laurence Lanfumey, and Rita Raisman-Vozari
February 2003, Brain research,
Copied contents to your clipboard!